Gilead Sciences Inc (GILD)vsTrane Technologies plc (TT)
GILD
Gilead Sciences Inc
$129.16
-1.35%
HEALTHCARE · Cap: $154.33B
TT
Trane Technologies plc
$463.76
+2.30%
INDUSTRIALS · Cap: $104.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Gilead Sciences Inc generates 38% more annual revenue ($29.74B vs $21.60B). GILD leads profitability with a 31.0% profit margin vs 13.4%. TT appears more attractively valued with a PEG of 2.01. GILD earns a higher WallStSmart Score of 68/100 (B-).
GILD
Strong Buy68
out of 100
Grade: B-
TT
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+43.9%
Fair Value
$220.62
Current Price
$129.16
$91.46 discount
Intrinsic value data unavailable for TT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 39.3%
Earnings expanding 54.8% YoY
Large-cap with strong market position
Attractively priced relative to earnings
Every $100 of equity generates 34 in profit
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
4.4% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 11.9x book value
Earnings declined 2.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : GILD
The strongest argument for GILD centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.0% and operating margin at 39.3%.
Bull Case : TT
The strongest argument for TT centers on Return on Equity, Market Cap.
Bear Case : GILD
The primary concerns for GILD are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : TT
The primary concerns for TT are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
TT carries more volatility with a beta of 1.21 — expect wider price swings.
TT is growing revenue faster at 6.0% — sustainability is the question.
GILD generates stronger free cash flow (2.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GILD scores higher overall (68/100 vs 52/100), backed by strong 31.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gilead Sciences Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Trane Technologies plc
INDUSTRIALS · BUILDING PRODUCTS & EQUIPMENT · USA
Trane Technologies plc is an American Irish domiciled diversified industrial manufacturing company. It is headquartered near Dublin, Ireland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?